Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, December 25, 2023

CNS Drug Delivery in Stroke: Improving Therapeutic Translation From the Bench to the Bedside

So you incompetently don't follow research at all?

If we had a complete database of stroke research this problem would be solved in no time. Getting thru the blood brain barrier, maybe one of these?

Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours

May 2020

LIPOSOMES FOR BRAIN DRUG DELIVERY  February 2020 

Exosomes as drug delivery vehicles for therapeutic proteins to the brain February 2019 

Miniaturized system delivers drugs to the brain with pinpoint accuracy February 2018 

Nanowires could be potential drug delivery tools for neurodegenerative diseases

 November 2017

Nose2Brain – Better Therapy for Multiple Sclerosis April 2017 

Novel Alzheimer's treatment uses microscopic droplets of fat to carry drugs into the brain October 2016 

New Technology Shows Promise for Delivery of Therapeutics to the Brain 

 October 2014

Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders July 2014 

Brain Targetting through Intranasal Route November 2013 

exosomes delivering drugs to brain March 2011

 And that is as far as I go back, so there are probably lots more.

 The latest here:

CNS Drug Delivery The latest here:in Stroke: Improving Therapeutic Translation From the Bench to the Bedside

Originally published22 Dec 2023https://doi.org/10.1161/STROKEAHA.123.043764Stroke. 2024;55:190–202

Abstract

Drug development for ischemic stroke is challenging as evidenced by the paucity of therapeutics that have advanced beyond a phase III trial. There are many reasons for this lack of clinical translation including factors related to the experimental design of preclinical studies. Often overlooked in therapeutic development for ischemic stroke is the requirement of effective drug delivery to the brain, which is critical for neuroprotective efficacy of several small and large molecule drugs. Advancing central nervous system drug delivery technologies implies a need for detailed comprehension of the blood-brain barrier (BBB) and neurovascular unit. Such knowledge will permit the innate biology of the BBB/neurovascular unit to be leveraged for improved bench-to-bedside translation of novel stroke therapeutics. In this review, we will highlight key aspects of BBB/neurovascular unit pathophysiology and describe state-of-the-art approaches for optimization of central nervous system drug delivery (ie, passive diffusion, mechanical opening of the BBB, liposomes/nanoparticles, transcytosis, intranasal drug administration). Additionally, we will discuss how endogenous BBB transporters represent the next frontier of drug delivery strategies for stroke. Overall, this review will provide cutting edge perspective on how central nervous system drug delivery must be considered for the advancement of new stroke drugs toward human trials.

Posted by at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)